Frazier-Backed Mavupharma Scores $20M to Fund STING Program Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Series A funding will be used primarily to advance Mavu’s lead drug candidates into the clinic. Source: BioSpace You Might Also Like Elite Pharma Reports Financial Results For The Fiscal Year Ended March 31, 2017 And Provides Conference Call Information June 14, 2017 <b>Luye Life Sciences</b> Expands Global Reach As New Boston R&D Center Opens July 16, 2017 Can-Fite BioPharma Release: Company Announces $5 Million Registered Direct Offering January 18, 2017
Elite Pharma Reports Financial Results For The Fiscal Year Ended March 31, 2017 And Provides Conference Call Information June 14, 2017